<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00806663</url>
  </required_header>
  <id_info>
    <org_study_id>C-II-005 /2008-001515-37</org_study_id>
    <nct_id>NCT00806663</nct_id>
  </id_info>
  <brief_title>FOLFIRI and Sunitinib in Metastatic Colorectal Cancer</brief_title>
  <official_title>A Prospective Angiogenic Imaging Study With DCE-MRI and DCE-USI in Patients With Colorectal Cancer and Liver Metastases Receiving Sunitinib in Addition to 5-FU, Folinic Acid and Irinotecan (FOLFIRI) as 1st Line Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Central European Society for Anticancer Drug Research</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Central European Society for Anticancer Drug Research</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open label single arm prospective multicenter Phase II study in around 20&#xD;
      patients. The primary objective of this study is to evaluate whether the addition of&#xD;
      sunitinib to FOLFIRI results in a significant reduction of tumor vessel permeability (TVP)&#xD;
      and blood flow (BF) measured by DCE-MRI and DCE-USI, measured on liver metastases.&#xD;
&#xD;
      Secondary objectives are antitumor response, time to progression (TTP), effect on&#xD;
      pharmacokinetics of sunitinib and biomarkers (VEGF und soluble VEGF-receptor) and&#xD;
      drug/treatment safety.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2008</start_date>
  <completion_date type="Actual">September 2011</completion_date>
  <primary_completion_date type="Actual">July 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>reduction of tumor vessel permeability (TVP) and blood flow (BF) measured by DCE-MRI and DCE-USI, measured on liver metastases.</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Antitumour response</measure>
    <time_frame>9 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to progression (TTP)</measure>
    <time_frame>9 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pharmacokinetics</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>drug treatment safety</measure>
    <time_frame>9 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">22</enrollment>
  <condition>Metastatic Colorectal Cancer</condition>
  <condition>Liver Metastases</condition>
  <arm_group>
    <arm_group_label>Sunitinib Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sutent sunitinib 37 mg once daily (4 weeks on/2 weeks off)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sunitinib added to FOLFIRI</intervention_name>
    <description>sunitinib 37 mg once daily (4 weeks on/2 weeks off)</description>
    <arm_group_label>Sunitinib Arm</arm_group_label>
    <other_name>Sutent</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult males and females: over 18 years of age.&#xD;
&#xD;
          -  Patients with histologically or cytologically confirmed colorectal cancer who will&#xD;
             receive their first palliative treatment.&#xD;
&#xD;
          -  Patients who have at least one measurable hepatic lesion of 2 cm or more according to&#xD;
             RECIST criteria.&#xD;
&#xD;
          -  ECOG 0 or 1.&#xD;
&#xD;
          -  Signed written informed consent.&#xD;
&#xD;
          -  White blood cell count (WBC)&gt;= 4x10^9/L with neutrophils &gt;= 1.5 x 10*9/L, platelet&#xD;
             count &gt;= 100x10*9/L, hemoglobin &gt;= 5.6 mmol/L (10 g/dL).&#xD;
&#xD;
          -  Total bilirubin =&lt; 2 x upper limit of normal.&#xD;
&#xD;
          -  AST and ALT =&lt; 2.5 x upper limit of normal, or =&lt; 5 x upper limit of normal in case of&#xD;
             liver metastases.&#xD;
&#xD;
          -  Serum creatinine =&lt; 1.5 x upper limit of normal or creatinine clearance &gt; 60 ml/min&#xD;
&#xD;
          -  Normal ECG without QT prolongation.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Resectable liver metastasis.&#xD;
&#xD;
          -  Adjuvant therapy with FOLFOX or 5-FU / Capecitabine =&lt; 6 months prior to treatment on&#xD;
             study or any previous palliative chemotherapy..&#xD;
&#xD;
          -  Any contraindication for FOLFIRI chemotherapy regimen.&#xD;
&#xD;
          -  Any investigational drug within the 30 days before inclusion.&#xD;
&#xD;
          -  Prior use of sunitinib or other multitarget tyrosine kinase inhibitors or VEGF pathway&#xD;
             directed treatments like bevacizumab.&#xD;
&#xD;
          -  Known or suspected allergy or hypersensitivity reaction to any of the components of&#xD;
             study treatments.&#xD;
&#xD;
          -  Pregnancy (absence to be confirmed by beta-hCG test) or lactation period&#xD;
&#xD;
          -  Men or women of child-bearing potential who are sexually active and unwilling to use a&#xD;
             medically acceptable method of contraception during the trial&#xD;
&#xD;
          -  Clinically symptomatic brain or meningeal metastasis. (known or suspected)&#xD;
&#xD;
          -  Cardiac arrhythmias requiring anti-arhythmics (excluding beta blockers or digoxin).&#xD;
&#xD;
          -  History of any of the following cardiac events within the past 6 months:&#xD;
&#xD;
               -  myocardial infarction (including severe/ unstable angina),&#xD;
&#xD;
               -  coronary/peripheral artery bypass graft,&#xD;
&#xD;
               -  congestive heart failure (CHF),&#xD;
&#xD;
               -  cerebrovascular accident,&#xD;
&#xD;
               -  transient ischemic attack pulmonary embolism.&#xD;
&#xD;
          -  History of clinically significant bleeding within the past 6 months, including gross&#xD;
             hemoptysis or haematuria, or underlying coagulopathy.&#xD;
&#xD;
          -  History of peptic ulcer disease, deep vein thrombosis, or other significant&#xD;
             thrombo-embolic event within the past 6 months.&#xD;
&#xD;
          -  Uncontrolled severe hypertension (failure of diastolic blood pressure to fall below 90&#xD;
             mm Hg despite the use of &gt;= 3 anti-hypertensive drugs.&#xD;
&#xD;
          -  Acute or sub-acute intestinal occlusion or history of inflammatory bowel disease or&#xD;
             chronic diarrhea.&#xD;
&#xD;
          -  Previous malignancy (other than colorectal cancer) in the last 5 years except basal&#xD;
             cell cancer of the skin, pre-invasive cancer of the cervix or superficial bladder&#xD;
             tumor [Ta, Tis and T1].&#xD;
&#xD;
          -  History of organ allograft&#xD;
&#xD;
          -  Treatment with potent CYP3A4 inhibitor within 7 days of sunitinib/placebo dosing or&#xD;
             with potent CYP3A4 inducer within 12 days of sunitinib/placebo dosing.&#xD;
&#xD;
          -  Prior full field radiotherapy =&lt; 4 weeks, or limited field radiotherapy, =&lt; to 2 weeks&#xD;
             prior to study enrollment; or previous radiation treatment &gt;30% of the bone marrow.&#xD;
&#xD;
          -  Major surgical procedure, open biopsy or significant traumatic injury within 4 weeks&#xD;
             before starting treatment; anticipation of need for major surgical procedure (e.g.&#xD;
             impending bowel obstruction) during the course of the study.&#xD;
&#xD;
          -  History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess&#xD;
             within 6 months prior to study enrollment, unless affected area has been removed&#xD;
             surgically.&#xD;
&#xD;
          -  Significant disease which, in the investigator's opinion would exclude the patient&#xD;
             from the study.&#xD;
&#xD;
          -  Patients with seizure and epileptic disorder or other conditions requiring medication&#xD;
             such as phenytoin, carbamazepin, phenobarbital.&#xD;
&#xD;
          -  Patients requiring long-term cortisone therapy.&#xD;
&#xD;
          -  Patients requiring oral anticoagulation treatment (marcoumar).&#xD;
&#xD;
          -  Known alcohol or drug abuse.&#xD;
&#xD;
          -  Medical or psychological conditions that would not permit the patient to complete the&#xD;
             study or sign informed consent.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Klaus Mross, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Klinik f체r Tumorbiologie</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Innere Univ.-Klinik u. Poliklinik Tumorforschung</name>
      <address>
        <city>Essen</city>
        <zip>D-45122</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinik f체r Tumorbiologie</name>
      <address>
        <city>Freiburg</city>
        <zip>D-79106</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Universit채tsklinik der Albert-Ludwigs-Universit채t Freiburg</name>
      <address>
        <city>Freiburg</city>
        <zip>D-79106</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Marienhospital</name>
      <address>
        <city>Herne</city>
        <zip>D-44625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>December 10, 2008</study_first_submitted>
  <study_first_submitted_qc>December 10, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 11, 2008</study_first_posted>
  <last_update_submitted>February 4, 2019</last_update_submitted>
  <last_update_submitted_qc>February 4, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 6, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>mCRC</keyword>
  <keyword>colorectal cancer</keyword>
  <keyword>FOLFIRI</keyword>
  <keyword>sunitinib</keyword>
  <keyword>DCE-MRI</keyword>
  <keyword>DCE-USI</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sunitinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

